ReviewImmunotherapy
Cemiplimab in the treatment of cutaneous squamous cell carcinoma.
Review in Immunotherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rapidly growing well-differentiated cutaneous squamous cell carcinoma of the scalp in a patient who was immunosuppressed.Skin health and disease · 2026Article
- Multimodal Analysis of Aggressive Multifocal Cutaneous Squamous Cell Carcinoma Associated with a Germline COL6A3 Truncating Variant: A Case Report.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have significantly transformed the treatment landscape of cutaneous squamous cell carcinoma (CSCC). Cemiplimab, a human IgG4 monoclonal antibody to the programmed death-1 (PD-1) receptor, has shown impressive response rates and durable disease control in patients with advanced CSCC, alongside a manageable safety profile. More recently, cemiplimab has demonstrated promising efficacy in both the adjuvant and neoadjuvant settings, with impressive improvements in disease-free survival and pathological response rates. This review provides a comprehensive overview of the current role of cemiplimab in the management of CSCC, highlighting key clinical trial data and real-world evidence on its efficacy and safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.